Skip to main content
Panacea Biotec Ltd. logo

Panacea Biotec Ltd. — Investor Relations & Filings

Ticker · PANACEABIO ISIN · INE922B01023 LEI · 3358001FA81ZQYDLO796 BSE.NS Manufacturing
Open in API
Filings indexed 794 across all filing types
Latest filing 2021-02-14 Regulatory Filings
Country IN India
Listing BSE.NS PANACEABIO

About Panacea Biotec Ltd.

https://www.panaceabiotec.com

Panacea Biotec Ltd. is a research-driven health management company specializing in the development, manufacturing, and marketing of vaccines, biopharmaceuticals, and pharmaceutical formulations. The organization focuses on therapeutic segments including organ transplantation, nephrology, oncology, diabetes, and pain management. Its vaccine portfolio supports global immunization initiatives, addressing diseases such as polio and hepatitis B through partnerships with international health agencies. The company operates integrated research and development centers and manufacturing facilities that adhere to international quality standards. Panacea Biotec emphasizes the creation of innovative drug delivery systems and complex generics to improve patient outcomes. Its operations are characterized by a commitment to biotechnology-led medical solutions and the production of affordable, high-quality therapeutic products for diverse global markets.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings
2021-02-14 English
Financial Result Updates
Regulatory Filings
2021-02-12 English
Outcome of Board Meeting
Regulatory Filings
2021-02-12 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges and depositories providing details of shares dematerialized during January 2021. It references Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, and includes annexures with data on shares dematerialized and a certificate from the Registrar and Transfer Agent. The content is a regulatory compliance update about share dematerialization status, not a financial report, earnings release, or management discussion. It is a formal regulatory filing informing stock exchanges and depositories about share dematerialization details. The document length is 4093 characters, which is relatively short and focused on regulatory compliance information. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-02-06 English
Copy of Newspaper Publication
Regulatory Filings
2021-02-05 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document text is extremely short (64 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, no report content, no announcements, or any other information to classify as a specific report type. Given the lack of content, the document cannot be classified as a report or announcement. According to the rules, such minimal content defaults to Regulatory Filings (RNS) as a fallback category.
2021-02-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.